FRANCE – Amolyt Pharma, a Lyon, France-based company specialized in developing therapeutic peptides for rare endocrine and related diseases, raised $138M in Series C funding.
The round was co-led by Sofinnova Partners and Intermediate Capital Group, with participation from Tekla Capital Investment LLC, CTI Life Sciences, Andera Partners, Novo Holdings, Kurma Partners, EQT Life Sciences, Innobio 2, Sectoral Asset Management, Pontifax, Orbimed, Mass General Brigham Ventures, ATEM, Credit Agricole Creation and Relyens Innovation Santé/Turenne Capital.The company intends to use the funds to advance its pipeline of therapeutics for rare endocrine and related disorders, including AZP-3601, now known as eneboparatide, for the treatment of hypoparathyroidism, and AZP-3813 for the treatment of acromegaly. Led by CEO Thierry Abribat, Amolyt Pharma is a clinical stage biotechnology company building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its development portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. 09/01/2023
